Outcomes of Sentinel Lymph Node Biopsy by Using Isosulfan Blue Dye Alone Technique in Early Breast Cancer Patients
Keywords:
Sentinel lymph node biopsy, Isosulfan blue dye, Identification rateAbstract
Background: Sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer with undetected axillary lymph node abnormalities is the current standard surgery. It is generally recommended that isosulfan blue and radiocolloid be injected together for a higher identification rate of the sentinel lymph nodes. But radiocolloids are expensive, specialized detection equipment and specialized staff are required. Therefore, it is the origin of this study to determine whether the injection of isosulfan blue injection alone, because it is cheap, safe and easy to access, will be able to provide standard sentinel lymph node identification result.
Methods: This is a retrospective study of breast cancer patients underwent SLNB by using isosulfan blue dye injection alone technique of Maharat Nakhon Ratchasima Hospital by Dr. Noppadol Trikunagonvong. From August 1st, 2016 to May 31st, 2022, there are 81 people.
Results: The mean age of the patients was 52.4 years (range, 31 to 71 years). Fifty-nine patients (72.84%) underwent mastectomy and 22 patients (27.16%) underwent breast conserving surgery. Mean (standard deviation) number of SLN were 3.73 (1.6) nodes. The identification rate of sentinel lymph nodes was 95.06%. The accuracy of frozen section report of our hospital was 97.4%. Fifty-one patients (66.23%) had negative SLNB and 26 patients (33.77%) had positive SLNB. ALND was reduced by 66.23%. There were 35 of 51 patients whose SLNB were negative and were followed for more than 2 years, 1 recurrence (2.85%) was found.
Conclusion: SLNB, using isosulfan blue dye alone technique, is a reliable, inexpensive, safe and simple surgery alternative.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
Halsted WS. I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 1894;20(5):497-555.
Li CZ, Zhang P, Li RW, et al. Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: A meta-analysis. Eur J Surg Oncol. 2015;41(8):958-66.
Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-401.
Giuliano AE, Jones RC, Brennan M, et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15(6):2345–50.
Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349(9069):1864-7.
Cody HS. Clinical aspects of sentinel node biopsy. Breast Cancer Res. 2001;3(2):104-8.
Tuttle TM, Colbert M, Christensen R, et al. Subareolar injection of 99mTc facilitates sentinel lymph node identification. Ann Surg Oncol. 2002;9(1):77-81.
Mathelin C, Croce S, Brasse D, et al. Methylene Blue Dye, an Accurate Dye for Sentinel Lymph Node Identification in Early Breast Cancer. Anticancer Res. 2009;29(10):4119-25.
Ratanawichitrasin A, Rojananin S, Bhothisuwan K, et al. Lymphatic Mapping with Isosulfan Blue and Sentinel Lymph Node Biopsy for Breast Cancer Patients. Thai J Surg. 1999;20(3):93-6.
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703–20.
Krag DN, Anderson SJ, Julian TB, et al. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. JCO. 2010;28(18_suppl):LBA505-LBA505.
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-33.
Julian TB, Anderson SJ, Krag DN, et al. 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. JCO. 2013;31(15_suppl):1000.
Xiang J, Huang S, Tuo Y, et al. Effect of breast-conserving surgery combined with sentinel lymph node biopsy and axillary preservation on the recurrence, metastasis, complications and cosmetic results of early breast cancer patients. Gland Surg. 2020;9(4):1019-25.
Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(5):561-4.
Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surgical Oncology. 1993;2(6):335-40.
Layeeque R, Kepple J, Henry-Tillman RS, et al. Intraoperative Subareolar Radioisotope Injection for Immediate Sentinel Lymph Node Biopsy. Annals of Surgery. 2004;239(6):841.
Fleming FJ, Hill AD, Kavanagh D, et al. Intradermal radioisotope injection optimises sentinel lymph node identification in breast cancer. Eur J Surg Oncol. 2003;29(10):835-8. doi:10.1016/j.ejso.2003.08.027.
Liu J, Huang L, Wang N, et al. Indocyanine green detects sentinel lymph nodes in early breast cancer. J Int Med Res. 2017;45(2):514-524. doi:10.1177/0300060516687149.
Lin J, Lin LS, Chen DR, et al. Indocyanine green fluorescence method for sentinel lymph node biopsy in breast cancer. Asian J Surg. 2020;43(12):1149-1153. doi:10.1016/j.asjsur.2020.02.003.
Areerattanavet K. Identification Rate of Sentinel Lymph Node Biopsy using Single Technique (Isosulfan Blue Dye) in Early Breast Cancer in Lopburi Cancer Hospital. J Dept Med Ser. 2021;46(3):73-80.
Ratchaworapong K, Thanawut S, Yodavudh S, et al. Rate of sentinel lymph node identification using isosulfan blue dye in breast cancer patients at Charoenkrung Pracharak Hospital, Thailand. Asian Biomedicine. 2014;8(4):517-24.
Kongdan Y, Chirappapha P, Lertsithichai P. Effectiveness and reliability of sentinel lymph node biopsy under local anesthesia for breast cancer. The Breast. 2008;17(5):528-31.
Kantaraksa N, Kongdan Y, Suvikapakornkul R, et al. The relative false negative rate of isosulfan blue in detecting sentinel lymph nodes in early breast cancer. J Med Assoc Thai. 2012;95(2):181-5.
Giuliano AE, McCall LM, Beitsch PD, et al. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. JCO. 2010;28(18_suppl):CRA506-CRA506.
Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918-26.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The Royal College of Surgeons of Thailand
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles must be contributed solely to The Thai Journal of Surgery and when published become the property of the Royal College of Surgeons of Thailand. The Royal College of Surgeons of Thailand reserves copyright on all published materials and such materials may not be reproduced in any form without the written permission.
